{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:15Z","timestamp":1780987995782,"version":"3.54.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11864-023-01112-0","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:02:00Z","timestamp":1688601720000},"page":"1259-1273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: a Review"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2014-9318","authenticated-orcid":false,"given":"Prioty","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"issue":"10","key":"1112_CR1","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.3324\/haematol.2017.185868","volume":"103","author":"A Mato","year":"2018","unstructured":"Mato A, Jahnke J, Li P, et al. Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. Haematologica. 2018;103(10):e462\u20135. https:\/\/doi.org\/10.3324\/haematol.2017.185868.","journal-title":"Haematologica."},{"key":"1112_CR2","unstructured":"Surveillance, Epidemiology, and End Results (SEER).\u00a0SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute.\u00a0Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries. 2023. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/.\u00a0[updated: 2023 Jun 8; cited 2023 Jun 26]"},{"issue":"4","key":"1112_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000510768","volume":"144","author":"P Smolewski","year":"2021","unstructured":"Smolewski P, Robak T. Current treatment of refractory\/relapsed chronic lymphocytic leukemia: a focus on novel drugs. Acta Haematologica. 2021;144(4):365\u201379. https:\/\/doi.org\/10.1159\/000510768.","journal-title":"Acta Haematologica."},{"issue":"25","key":"1112_CR4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood."},{"issue":"1","key":"1112_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals Oncol. 2021;32(1):23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019.","journal-title":"Annals Oncol."},{"key":"1112_CR6","doi-asserted-by":"publisher","unstructured":"Woyach JA. Management of relapsed\/refractory chronic lymphocytic leukemia. Am J Hematol. 2022;97(S2). https:\/\/doi.org\/10.1002\/ajh.26683.","DOI":"10.1002\/ajh.26683"},{"issue":"12","key":"1112_CR7","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/ajh.24808","volume":"92","author":"J Crombie","year":"2017","unstructured":"Crombie J, Davids MS. <i>IGHV<\/i>mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017;92(12):1393\u20137. https:\/\/doi.org\/10.1002\/ajh.24808.","journal-title":"Am J Hematol."},{"issue":"3","key":"1112_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/nejmoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England J Med. 2014;371(3):213\u201323. https:\/\/doi.org\/10.1056\/nejmoa1400376.","journal-title":"New England J Med."},{"issue":"12","key":"1112_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"\u2022 Munir T, Brown JR, O\u2019Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353\u201363. https:\/\/doi.org\/10.1002\/ajh.25638. Of import due to the context of this study in establishing long-term safety and durability data for the first novel targeted therapeutic agent avialable in CLL","journal-title":"Am J Hematol."},{"issue":"10","key":"1112_CR10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","volume":"17","author":"S O\u2019Brien","year":"2016","unstructured":"O\u2019Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(16)30212-1.","journal-title":"Lancet Oncol."},{"issue":"20","key":"1112_CR11","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/cncr.29566","volume":"121","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, O'Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121(20):3612\u201321. https:\/\/doi.org\/10.1002\/cncr.29566.","journal-title":"Cancer."},{"issue":"5","key":"1112_CR12","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematol. 2018;103(5):874\u20139. https:\/\/doi.org\/10.3324\/haematol.2017.182907.","journal-title":"Haematol."},{"issue":"5","key":"1112_CR13","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.3324\/haematol.2018.198820","volume":"104","author":"M Winqvist","year":"2019","unstructured":"Winqvist M, Andersson P-O, Asklid A, et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Haematol. 2019;104(5):e208\u201310. https:\/\/doi.org\/10.3324\/haematol.2018.198820.","journal-title":"Haematol."},{"issue":"35","key":"1112_CR14","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.2217\/fon-2021-0964","volume":"17","author":"JZ Hou","year":"2021","unstructured":"Hou JZ, Ryan K, Du S, et al. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Future Oncol. 2021;17(35):4959\u201369. https:\/\/doi.org\/10.2217\/fon-2021-0964.","journal-title":"Future Oncol."},{"issue":"18","key":"1112_CR15","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","volume":"129","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581\u20134. https:\/\/doi.org\/10.1182\/blood-2016-10-742437.","journal-title":"Blood."},{"key":"1112_CR16","doi-asserted-by":"publisher","unstructured":"Boriani G, Menna P, Morgagni R, Minotti G, Vitolo M. Ibrutinib and Bruton\u2019s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias\/sudden cardiac death. Chemother. 2022. https:\/\/doi.org\/10.1159\/000528019.","DOI":"10.1159\/000528019"},{"issue":"11","key":"1112_CR17","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","volume":"23","author":"SEM Herman","year":"2017","unstructured":"Herman SEM, Montraveta A, Niemann CU, et al. The Bruton tyrosine kinase (BTK) Inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0463.","journal-title":"Clin Cancer Res."},{"issue":"12","key":"1112_CR18","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","volume":"6","author":"P Ghia","year":"2022","unstructured":"\u2022 Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere. 2022;6(12):e801. https:\/\/doi.org\/10.1097\/HS9.0000000000000801. Of importance as the first registrational trial to establish a next-generation BTK inhibitor","journal-title":"Hemasphere"},{"issue":"4","key":"1112_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"\u2022\u2022 Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582. Of significant importance as the first head to head clinical trial of BTK inhibitors to establish clinical superiority over ibrutinib.","journal-title":"N Engl J Med."},{"issue":"10277","key":"1112_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"\u2022\u2022 Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(21)00224-5. Of significant importance given the novel non-covalent BTKi mechanism of overcoming BTK resistance muations.","journal-title":"Lancet."},{"key":"1112_CR21","doi-asserted-by":"publisher","unstructured":"Gomez EB, Ebata K, Randeria HS, et al. Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2022018674.","DOI":"10.1182\/blood.2022018674"},{"issue":"31","key":"1112_CR22","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/jco.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"\u2022 Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441\u201352. https:\/\/doi.org\/10.1200\/jco.21.01210. Of importance as the first head to head study of covalent BTKi.","journal-title":"J Clin Oncol."},{"issue":"8","key":"1112_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC, et al. Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med. 2022;386(8):735\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2114110.","journal-title":"N Engl J Med."},{"issue":"20","key":"1112_CR24","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","volume":"6","author":"P Blombery","year":"2022","unstructured":"Blombery P, Thompson ER, Lew TE, et al. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv. 2022;6(20):5589\u201392. https:\/\/doi.org\/10.1182\/bloodadvances.2022008325.","journal-title":"Blood Adv."},{"issue":"24","key":"1112_CR25","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370(24):2352\u20134. https:\/\/doi.org\/10.1056\/NEJMc1402716.","journal-title":"N Engl J Med."},{"issue":"1","key":"1112_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ijc.32502","volume":"146","author":"A Gango","year":"2020","unstructured":"Gango A, Alpar D, Galik B, et al. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer. 2020;146(1):85\u201393. https:\/\/doi.org\/10.1002\/ijc.32502.","journal-title":"Int J Cancer."},{"issue":"4","key":"1112_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"\u2022\u2022 Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1513257. Of significant importance establishing viability of BCL2 targeting as an effective treatment strategy in relapsed CLL.","journal-title":"N Engl J Med."},{"issue":"19","key":"1112_CR28","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973\u201380. https:\/\/doi.org\/10.1200\/JCO.2017.76.6840.","journal-title":"J Clin Oncol."},{"issue":"6","key":"1112_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768\u201378. https:\/\/doi.org\/10.1016\/S1470-2045(16)30019-5.","journal-title":"Lancet Oncol."},{"issue":"8","key":"1112_CR30","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood.2021012775","volume":"139","author":"P Blombery","year":"2022","unstructured":"Blombery P, Lew TE, Dengler MA, et al. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood. 2022;139(8):1198\u2013207. https:\/\/doi.org\/10.1182\/blood.2021012775.","journal-title":"Blood."},{"issue":"12","key":"1112_CR31","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"\u2022\u2022 Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1713976. Of significant importance establishing the definitive venetoclax based treatment regimen in R\/R CLL.]","journal-title":"N Engl J Med."},{"key":"1112_CR32","doi-asserted-by":"crossref","unstructured":"Kater A KT, Eichhorst B, et al. Five-year analysis of\u00a0 Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) patients (pts) following fixed-duration Venetoclax-rituximab (VenR) therapy (Tx) [Abstract 125]. In: Am Soc Hematol Annual Meet 2021. Atlanta, Georgia, USA.","DOI":"10.1182\/blood-2020-136109"},{"issue":"8","key":"1112_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"\u2022 Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140(8):839\u201350. https:\/\/doi.org\/10.1182\/blood.2021015014. Of importance in understanding MRD-guided therapy and response duration.","journal-title":"Blood."},{"key":"1112_CR34","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.lrr.2021.100266","volume":"16","author":"MT Siddiqui","year":"2021","unstructured":"Siddiqui MT, Price A, Ferrajoli A, Borthakur G. Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax. Leuk Res Rep. 2021;16:100266. https:\/\/doi.org\/10.1016\/j.lrr.2021.100266.","journal-title":"Leuk Res Rep."},{"issue":"1","key":"1112_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/bloodadvances.2019000864","volume":"4","author":"TE Lew","year":"2020","unstructured":"Lew TE, Anderson MA, Lin VS, et al. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Adv. 2020;4(1):165\u201373. https:\/\/doi.org\/10.1182\/bloodadvances.2019000864.","journal-title":"Blood Adv."},{"issue":"16","key":"1112_CR36","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37(16):1391\u2013402. https:\/\/doi.org\/10.1200\/JCO.18.01460.","journal-title":"J Clin Oncol."},{"issue":"16","key":"1112_CR37","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/cncr.30069","volume":"122","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Stingo F, Keating MJ, et al. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016;122(16):2505\u201311. https:\/\/doi.org\/10.1002\/cncr.30069.","journal-title":"Cancer."},{"issue":"23","key":"1112_CR38","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018;132(23):2446\u201355. https:\/\/doi.org\/10.1182\/blood-2018-05-850461.","journal-title":"Blood."},{"key":"1112_CR39","unstructured":"Meeting ODAC. Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in hematologic malignancies. 2022.\u00a0https:\/\/www.fda.gov\/media\/157762\/download.\u00a0Accessed May\/Jun 2022."},{"issue":"5","key":"1112_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/13543784.2017.1313230","volume":"26","author":"G Itchaki","year":"2017","unstructured":"Itchaki G, Brown JR. Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26(5):633\u201350. https:\/\/doi.org\/10.1080\/13543784.2017.1313230.","journal-title":"Expert Opin Investig Drugs."},{"issue":"5","key":"1112_CR41","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","volume":"31","author":"XC Badoux","year":"2013","unstructured":"Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;31(5):584\u201391. https:\/\/doi.org\/10.1200\/JCO.2012.42.8623.","journal-title":"J Clin Oncol."},{"issue":"5","key":"1112_CR42","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1056\/nejmc2005943","volume":"383","author":"IE Ahn","year":"2020","unstructured":"Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with <i>TP53<\/i> alterations. New England J Med. 2020;383(5):498\u2013500. https:\/\/doi.org\/10.1056\/nejmc2005943.","journal-title":"New England J Med."},{"issue":"18","key":"1112_CR43","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","volume":"128","author":"AR Mato","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199\u2013205. https:\/\/doi.org\/10.1182\/blood-2016-05-716977.","journal-title":"Blood."},{"issue":"5","key":"1112_CR44","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","volume":"28","author":"AR Mato","year":"2017","unstructured":"\u2022 Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx031. Of importance as a retrospective study to guide sequencing of novel agents.","journal-title":"Ann Oncol."},{"key":"1112_CR45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/asheducation-2017.1.346","volume":"1","author":"MS Davids","year":"2017","unstructured":"Davids MS. How should we sequence and combine novel therapies in CLL? Hematology; Am Soc Hematol Educ Program. 2017;1:346\u201353.","journal-title":"Hematology; Am Soc Hematol Educ Program."},{"issue":"1","key":"1112_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","volume":"13","author":"W Xu","year":"2020","unstructured":"Xu W, Yang S, Zhou K, et al. Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13(1):48. https:\/\/doi.org\/10.1186\/s13045-020-00884-4.","journal-title":"J Hematol Oncol."},{"issue":"11","key":"1112_CR47","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139. https:\/\/doi.org\/10.1182\/blood.2019001160.","journal-title":"Blood."},{"issue":"9","key":"1112_CR48","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","volume":"3","author":"FT Awan","year":"2019","unstructured":"Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3(9):1553\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2018030007.","journal-title":"Blood Adv."},{"issue":"22","key":"1112_CR49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1182\/blood.V128.22.637.637","volume":"128","author":"MYC Jeffrey Jones","year":"2016","unstructured":"Jeffrey Jones MYC, Mato AR, Furman RR, Davids MS, Heffner LT, Cheson BD, Lamanna N, Barr PM, Eradat H, Halwani A, Chyla B, Zhu M, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Coutre SE. Venetoclax (VEN) Monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood. 2016;128(22):637.","journal-title":"Blood."},{"issue":"1","key":"1112_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. The Lancet Oncol. 2018;19(1):65\u201375. https:\/\/doi.org\/10.1016\/s1470-2045(17)30909-9.","journal-title":"The Lancet Oncol."},{"issue":"25","key":"1112_CR51","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1182\/blood.2020004782","volume":"135","author":"VS Lin","year":"2020","unstructured":"Lin VS, Lew TE, Handunnetti SM, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood. 2020;135(25):2266\u201370. (In eng). https:\/\/doi.org\/10.1182\/blood.2020004782.","journal-title":"Blood."},{"issue":"14","key":"1112_CR52","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","volume":"26","author":"AR Mato","year":"2020","unstructured":"Mato AR, Roeker LE, Jacobs R, et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res. 2020;26(14):3589\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3815.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"1112_CR53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1182\/blood.2020008502","volume":"138","author":"TE Lew","year":"2021","unstructured":"Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361\u20139. https:\/\/doi.org\/10.1182\/blood.2020008502.","journal-title":"Blood."},{"issue":"15","key":"1112_CR54","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","volume":"6","author":"MC Thompson","year":"2022","unstructured":"Thompson MC, Harrup RA, Coombs CC, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022;6(15):4553\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2022007812.","journal-title":"Blood Adv."},{"issue":"1","key":"1112_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/hematology.2022000344","volume":"2022","author":"L Scarf\u00f2","year":"2022","unstructured":"Scarf\u00f2 L. Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax. Hematol Am Soc Hematol Educ Program. 2022;2022(1):316\u201322. (In eng). https:\/\/doi.org\/10.1182\/hematology.2022000344.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"20","key":"1112_CR56","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","volume":"5","author":"TE Lew","year":"2021","unstructured":"Lew TE, Lin VS, Cliff ER, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5(20):4054\u20138. (In eng). https:\/\/doi.org\/10.1182\/bloodadvances.2021005083.","journal-title":"Blood Adv."},{"issue":"12","key":"1112_CR57","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2017-04-775841","volume":"130","author":"I Kramer","year":"2017","unstructured":"Kramer I, Stilgenbauer S, Dietrich S, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017;130(12):1477\u201380. https:\/\/doi.org\/10.1182\/blood-2017-04-775841.","journal-title":"Blood."},{"issue":"30","key":"1112_CR58","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722\u20139. https:\/\/doi.org\/10.1200\/JCO.19.00894.","journal-title":"J Clin Oncol."},{"issue":"31","key":"1112_CR59","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1200\/JCO.20.00491","volume":"38","author":"KA Rogers","year":"2020","unstructured":"Rogers KA, Huang Y, Ruppert AS, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(31):3626\u201337. https:\/\/doi.org\/10.1200\/JCO.20.00491.","journal-title":"J Clin Oncol."},{"issue":"22","key":"1112_CR60","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139(22):3278\u201389. https:\/\/doi.org\/10.1182\/blood.2021014488.","journal-title":"Blood."},{"key":"1112_CR61","doi-asserted-by":"publisher","unstructured":"Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evidence. 2022;1(7). https:\/\/doi.org\/10.1056\/evidoa2200006.","DOI":"10.1056\/evidoa2200006"},{"issue":"Supplement 1","key":"1112_CR62","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/blood-2022-164772","volume":"140","author":"AR Mato","year":"2022","unstructured":"Mato AR, Wierda WG, Ai WZ, et al. NX-2127-001, a First-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies. Blood. 2022;140(Supplement 1):2329\u201332. https:\/\/doi.org\/10.1182\/blood-2022-164772.","journal-title":"Blood."},{"issue":"Supplement 1","key":"1112_CR63","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2021-146563","volume":"138","author":"AP Kater","year":"2021","unstructured":"Kater AP, Christensen JH, Bentzen HH, et al. Subcutaneous epcoritamab in patients with relapsed\/refractory chronic lymphocytic leukemia: preliminary results from the Epcore CLL-1 trial. Blood. 2021;138(Supplement 1):2627\u20137. https:\/\/doi.org\/10.1182\/blood-2021-146563.","journal-title":"Blood."},{"issue":"5","key":"1112_CR64","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.21.00931","volume":"40","author":"LE Budde","year":"2022","unstructured":"Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481\u201391. https:\/\/doi.org\/10.1200\/JCO.21.00931.","journal-title":"J Clin Oncol."},{"issue":"Supplement 1","key":"1112_CR65","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1182\/blood-2018-99-115418","volume":"132","author":"SI Gill","year":"2018","unstructured":"Gill SI, Vides V, Frey NV, et al. Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate. Blood. 2018;132(Supplement 1):298\u20138. https:\/\/doi.org\/10.1182\/blood-2018-99-115418.","journal-title":"Blood."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01112-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:18:12Z","timestamp":1693808292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01112-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01112-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"15 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"PI: <i>Consultant<\/i>: AbbVie, AstraZeneca, BeiGene, DAVA Oncology, LOXO Oncology; <i>Speaker:<\/i> Targeted Oncology, The Video Journal of Hematologic Oncology (VJHemOnc).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}